SunTrust Robinson Humphrey Downgrades Juno Therapeutics (JUNO) to Hold
SunTrust Robinson Humphrey downgraded Juno Therapeutics (NASDAQ: JUNO) from Buy to Hold with a price target of $25.00 (from $48.00) after the ROCKET study evaluating JCAR015 in no-option Adult ALL was placed on clinical hold for the second time.
The analyst sees reduced visibility and increased uncertainty, and have conservatively removed ALL from the model.
For an analyst ratings summary and ratings history on Juno Therapeutics click here. For more ratings news on Juno Therapeutics click here.
Shares of Juno Therapeutics closed at $22.56 yesterday.